Biomedical Engineering Reference
In-Depth Information
[69]
Shishodia, S., Koul, D., and Aggarwal, B.B., Cyclooxygenase (COX)-2 inhibitor
celecoxib abrogates TNF-induced NF-kappaB activation through inhibition of
activation of IkappaBalpha kinase and Akt in human non-small cell lung carci-
noma: Correlation with suppression of COX-2 synthesis,
J. Immunol.,
173, 2011,
2004.
[70]
Smalley, W.E. and DuBois, R.N., Colorectal cancer and nonsteroidal anti-inflamma-
tory drugs,
Adv. Pharmacol.,
39, 1, 1997.
[71]
Thun, M.J., Henley, S.J., and Patrono, C., Nonsteroidal anti-inflammatory drugs as
anticancer agents: Mechanistic, pharmacologic, and clinical issues,
J. Natl. Cancer
Inst.,
94, 252, 2002.
[72]
Harris, R.E., Chlebowski, R.T., Jackson, R.D. et al., Breast cancer and nonsteroidal
anti-inflammatory drugs: Prospective results from the Women's Health Initiative,
Cancer Res.,
63, 6096, 2003.
[73]
Steinbach, G., Lynch, P.M., Phillips, R.K. et al., The effect of celecoxib, a cycloox-
ygenase-2 inhibitor, in familial adenomatous polyposis,
N. Engl. J. Med.,
342, 1946,
2000.
[74]
Kismet, K., Akay, M.T., Abbasoglu, O. et al., Celecoxib: A potent cyclooxygenase-
2 inhibitor in cancer prevention,
Cancer Detect. Prev.,
28, 127, 2004.
[75]
Tegeder, I., Niederberger, E., Israr, E. et al., Inhibition of NF-kappaB and AP-1
activation by R- and S-flurbiprofen,
FASEB J.,
15, 2, 2001.
[76]
Brune, K., Beck, W.S., Geisslinger, G. et al., Aspirin-like drugs may block pain
independently of prostaglandin synthesis inhibition,
Experientia,
47, 257, 1991.
[77]
Almawi, W.Y. and Melemedjian, O.K., Molecular mechanisms of glucocorticoid
antiproliferative effects: Antagonism of transcription factor activity by glucocorticoid
receptor,
J. Leukoc. Biol.,
71, 9, 2002.
[78]
Smoak, K.A. and Cidlowski, J.A., Mechanisms of glucocorticoid receptor signaling
during inflammation,
Mech. Ageing Dev.,
125, 697, 2004.
[79]
Scheinman, R.I., Cogswell, P.C., Lofquist, A.K. et al., Role of transcriptional activa-
tion of IkappaBalpha in mediation of immunosuppression by glucocorticoids,
Sci-
ence,
270, 283, 1995.
[80]
Auphan, N., DiDonato, J.A., Rosette, C. et al., Immunosuppression by glucocorti-
coids: Inhibition of NF-kappaB activity through induction of IkappaB synthesis,
Science,
270, 286, 1995.
[81]
Aljada, A., Ghanim, H., Assian, E. et al., Increased IkappaB expression and dimin-
ished nuclear NF-kappaB in human mononuclear cells following hydrocortisone
injection,
J. Clin. Endocrinol. Metab.,
84, 3386, 1999.
[82]
De Bosscher, K., Vanden Berghe, W., and Haegeman, G., The interplay between the
glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: Molecular
mechanisms for gene repression,
Endocr. Rev.,
24, 488, 2003.
[83]
Kleinert, H., Euchenhofer, C., Ihrig-Biedert, I. et al., Glucocorticoids inhibit the
induction of nitric oxide synthase II by down-regulating cytokine-induced activity of
transcription factor nuclear factor-kappaB,
Mol. Pharmacol.,
49, 15, 1996.
[84]
De Bosscher, K., Schmitz, M.L., Vanden Berghe, W. et al., Glucocorticoid-mediated
repression of nuclear factor-kappaB-dependent transcription involves direct interfer-
ence with transactivation,
Proc. Natl. Acad. Sci. USA,
94, 13504, 1997.
[85]
Adcock, I.M., Brown, C.R., Gelder, C.M. et al., Effects of glucocorticoids on tran-
scription factor activation in human peripheral blood mononuclear cells,
Am. J.
Physiol.,
268, C331, 1995.
